Clinical Trial Update: A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial comparing obinutuzumab plus zanubrutinib versus obinutuzumab alone in relapsed/refractory follicular lymphoma; the study has completed and results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• BRUKINSA (ZANUBRUTINIB)
• Gazyva (Obinutuzumab)

Snippet

Sponsor: BeiGene | Conditions: Relapsed/Refractory Follicular Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2024-04-30